Labiotech.eu

News and Trends 10 Sep 2015

Roche adds AveXis to its SMA portfolio – determined to dominate market

Swiss Roche is looking to dominate market in Spinal Muscular Atrophy (SMA) research, now also investing in AveXis as part of €58M series D investment in their SMA one-time treatment pipeline. Other veteran VC parties include Deerfield Management and Venrock, with new investors also looking to claim a stake in AveXis SMA candidate treatment. SMA […]

September 10, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 10 Sep 2015

CureVac, the mRNA Therapy Leader, is invading Moderna’s Homeland!

One more hit to Moderna Therapeutics struck by its German competitor CureVac! The Tübingen-based company just announced the opening of its subsidiary in Boston – hometown of Moderna – and a research collaboration with the U.S. non-profit International AIDS Vaccine Initiative (IAVI) to develop a mRNA-based HIV treatment. CureVac, today announced the official launch of its U.S. operations in […]

September 10, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 10 Sep 2015

Genkyotex’ NOX inhibitor candidate Fails to follow through on Phase II

The French biotech Genkyotex has announced Phase II results for GKT137831 in diabetic kidney disease. The NOX1-4 inhibitor failed to reduce albuminuria. Genkyotex focuses on developing inhibitors of nicotinamide adenine dinucleotide phosphate-oxidase (NADPH) enzymes which are expressed by the NOX-gene family (NOX 1-5). NOX enzymes generate reactive oxidative species (ROS) which if overproduced, can cause […]

September 10, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 10 Sep 2015

Debiopharm teams up with Solid Biosciences to treat DMD

The Debiopharm Group, headquartered in Lausanne (Switzerland) has announced its Alisporovir brand will under-go preclinical trials to treat Duchenne Muscular Dystrophy (DMD) in collaboration with Solid Biosciences, a Cambridge (MA) biotech dedicated to research of DMD. The Debiopharm Group has been around for over 40 years, with 4 international subsidiary companies within the Swiss-based group. […]

September 10, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 9 Sep 2015

Encouraging results from Tedopi Phase II trials in patients with brain metastases

French Immuno-oncology Biotech OSE Pharma has announced its phase II results for Tedopi trials showing outcome for patients with brain metastases. Announced at the World Conference on Lung Cancer in Denver (US), OSE Pharma revealed how Tedopi had shown interesting results in patients diagnosed with brain metastases from advanced non-small cell lung cancer. Advanced non-small […]

September 9, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 9 Sep 2015

FDA will use a European Bioinformatics tool to keep patients safe

Molecular Health, a bioinformatics company based in Heidelberg, Germany, today announced that it will enter a commercial-licensing agreement with the US Food and Drugs Standard Agency (FDA) to implement their new bioanalytical product SafetyMAP to analyse risk of marketed drugs. Molecular Health (Labiotech Map Profile here), partnered with MD Anderson (TX) early on, doing consultancy […]

September 9, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 9 Sep 2015

Kymab: One Multi-Award Winning Biotech Company Worth Watching!

Kymab is the European biotech to watch! Based in Cambridge (UK), the company has developed the Kymouse platform, with a unique approach to antibody delivery that has allowed this biotech to advance drug and vaccine discovery in a range of key medical research areas including HIV, malaria, cancers and autoimmune diseases. Kymab’s golden egg lies in the […]

September 9, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 8 Sep 2015

The First Biosimilar reached the US market… and it’s from Novartis

Biosimilar or copies of biological drugs are arriving on the market. After Europe, US gets its first Biosimilar too. The drug is produced by Novartis generic subsidiary, Sandoz and it will compete with Amgen‘s blockbuster drug Neupogen. When a drug generates $1.2Bn of annual revenues and its patent has expired, which company on earth wouldn’t be […]

September 8, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 8 Sep 2015

Major EU VCs invest €36.6M into Mallorcan hemodyalisis treatment

Ysios Capital is the leading investor on Baleric Island based Sanifit (Spain) which has developed a new candidate looking to treat Calciphylaxis and patients with renal diseases requiring hemodyalysis. Other lead VCs are looking to also invest, with interest from Forbion Partners (Nl) and Edmond de Rothschild (Fr) to name a few. Its series C […]

September 8, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 8 Sep 2015

Wasp venom kills Cancer cells

Side effects of cancer treatments are almost as feared as the disease itself. But what if we could selectively destroy cancer cells without harming normal cells? Wasp venom might hold the secret to this largely awaited solution, as researchers from São Paulo State University and University of Leeds unraveled the mechanism of its cancer-targeting toxin. […]

September 8, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 7 Sep 2015

Biotech Crowdfunding in Europe: Trendy but only 0.2% of total VC money raised since 2010

Figures for the amount raised for EU biotechs since 2010 suggest although crowdfunding is considered a massive springboard for small startups, in reality, it has a much more limited range of use. Perhaps we have too high an ambition for crowdfunding as a financial tool for biotech? Crowdfunding is in the general media so often […]

September 7, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 7 Sep 2015

A Slice of Europe: MD Anderson looks to invest in EU Immuno-Oncology

MD Anderson is expanding its Immatics sharehold to spawn new Houston-based subsidiary Immatics US through investing into a $60M (€54M) pot. Also partnering up with French CAR-T pioneers Cellectis, and collaborating with German Merck, MD Anderson is seemingly wanting to immerse itself in the European immuno-oncology field. As a shareholder in the German cancer immunotherapy […]

September 7, 2015 - 3 minutesmins - By Dani Bancroft

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Roche adds AveXis to its SMA portfolio – determined to dominate market

CureVac, the mRNA Therapy Leader, is invading Moderna’s Homeland!

Genkyotex’ NOX inhibitor candidate Fails to follow through on Phase II

Debiopharm teams up with Solid Biosciences to treat DMD

Encouraging results from Tedopi Phase II trials in patients with brain metastases

FDA will use a European Bioinformatics tool to keep patients safe

Kymab: One Multi-Award Winning Biotech Company Worth Watching!

The First Biosimilar reached the US market… and it’s from Novartis

Major EU VCs invest €36.6M into Mallorcan hemodyalisis treatment

Wasp venom kills Cancer cells

Biotech Crowdfunding in Europe: Trendy but only 0.2% of total VC money raised since 2010

A Slice of Europe: MD Anderson looks to invest in EU Immuno-Oncology

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!